Table 2. Patient characteristics stratified by painDETECT classification-group.
| n |
<13 |
PDQ score 13–18 |
>18 |
P-value |
||
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Patients, total (n) | RA | 3826 | 2136 | 903 | 787 | <0.001† |
| PsA | 1180 | 527 | 321 | 332 | <0.001† | |
| SpA | 1093 | 598 | 268 | 227 | <0.001† | |
| Female sex n(%)a | RA | 2766 | 1455 (68) | 674 (75) | 637 (81) | <0.001† |
| PsA | 666 | 235 (45) | 193 (60) | 238 (72) | <0.001† | |
| SpA | 436 | 194(32) | 123 (46) | 119 (52) | <0.001† | |
| Age (yrs) | RA | 3826 | 61 (52–69) | 59 (51–67) | 59 (51–66) | <0.001† |
| PsA | 1180 | 53 (43–61) | 52 (44–60) | 52 (42–60) | 0.227 | |
| SpA | 1093 | 45 (36–55) | 45 (37–55) | 43 (36–53) | 0.213 | |
| Disease durationb | RA | 3470 | 8(3–16) | 8(3–15) | 8(3–15) | 0.573 |
| PsA | 1000 | 7 (3–12) | 5 (2–10) | 5 (2–10) | 0.004 | |
| SpA | 953 | 7 (3–15) | 5 (2–10) | 4 (2–10) | 0.001 | |
| Treatment intensity | ||||||
| DMARDS n(%) | RA | 3216 | 1829(86) | 749(83) | 647(82) | 0.035 |
| PsA | 792 | 349(66) | 222(69) | 221(67) | 0.656 | |
| SpA | 237 | 122(20) | 62(23) | 53(23) | 0.527 | |
| DMARDS>1c | RA | 777 | 395(18) | 197(22) | 185(24) | 0.005 |
| PsA | 79 | 27 (5) | 25(8) | 27(8) | 0.150 | |
| SpA | 18 | 12 (2) | 3 (1) | 3 (1) | 0.581 | |
| Current bio n(%) | RA | 1341 | 730(34) | 328(36) | 283(36) | 0.439 |
| PsA | 458 | 212(40) | 121(38) | 125(38) | 0.670 | |
| SpA | 646 | 362 (61) | 153(57) | 131 (58) | 0.566 | |
| Bio >1d | RA | 875 | 422 (50) | 240 (59) | 213 (59) | 0.002 |
| PsA | 263 | 88 (36) | 72 (51) | 103 (61) | <0.001† | |
| SpA | 349 | 162(40) | 93 (49) | 94 (59) | 0.003 | |
| DMARDs previous bioe | RA | 204 | 80 (4) | 60 (7) | 64 (8) | <0.001† |
| PsA | 59 | 20 (4) | 13(4) | 26(8) | 0.020 | |
| SpA | 11 | 7 (1) | 7(3) | 4 (2) | 0.302 | |
| Prednisolone n(%) | RA | 376 | 188 (9) | 87 (10) | 101 (13) | 0.005 |
| PsA | 28 | 12 (2) | 6 (2) | 10 (3) | 0.619 | |
| SpA | 11 | 8 (1) | 2 (1) | 1 (0.5) | 0.456 | |
| PROs | ||||||
| VAS pain | RA | 3508 | 26 (14–44) | 43 (27–61) | 61 (43–77) | <0.001† |
| PsA | 1071 | 27 (15–46) | 49.5 (29–69) | 69 (52–81) | <0.001† | |
| SpA | 995 | 30 (16–53) | 53 (36–71) | 68.5 (52–82) | <0.001† | |
| VAS fatigue | RA | 3508 | 34 (17–57) | 54 (34–72) | 72 (54–85) | <0.001† |
| PsA | 1070 | 35 (17–57) | 63.5 (40–80) | 78 (62–90) | <0.001† | |
| SpA | 995 | 40 (22.5–66) | 65 (41.5–81) | 77 (60–88) | <0.001† | |
| VAS GH | RA | 3522 | 29 (15–53) | 51 (31–68) | 70 (52–84) | <0.001† |
| PsA | 1071 | 30 (15–57) | 58 (34–78) | 77 (59–89) | <0.001† | |
| SpA | 994 | 33.5 (19–56) | 63 (39.5–77.5) | 75 (59–87) | <0.001† | |
| HAQ | RA | 3506 | 0.5 (0.125–1) | 1 (0.5–1.375) | 1.375(1–1.875) | <0.001† |
| PsA | 1046 | 0.375(0.125–0.75) | 0.875(0.5–1.375) | 1.375(1–1.875) | <0.001† | |
| BASDAI | PsA | 1002 | 29 (15–46) | 53 (36–68) | 70 (55–83) | <0.001† |
| SpA | 923 | 31.5 (17–48) | 53 (35–66) | 68 (53–79) | <0.001† | |
| BASFI | PsA | 1001 | 22 (8–38) | 42.5 (26–61) | 65 (46–81) | <0.001† |
| SpA | 921 | 23 (11–43) | 38 (21–58) | 58 (41–77) | <0.001† | |
| Disease activity scores | ||||||
| VAS doctor | RA | 3058 | 7 (3–14) | 10 (4–19) | 13 (6.5–26) | <0.001† |
| PsA | 900 | 8 (3–15) | 10 (5–20) | 15 (7–25) | <0.001† | |
| SpA | 609 | 6 (2–15) | 9 (4–16) | 12 (5–25) | <0.001† | |
| DAS28-CRP | RA | 3046 | 2.4 (1.9–3.3) | 3(2.3–3.9) | 3.7 (2.8–4.7) | <0.001† |
| PsA | 825 | 2.4 (1.8–3.0) | 3.1(2.3–3.9) | 3.7 (2.7–4.6) | <0.001† | |
| SJC | RA | 3282 | 0 (0–1) | 0 (0–2) | 0 (0–2) | <0.001† |
| PsA | 946 | 0 (0–0) | 0 (0–1) | 0 (0–1) | 0.007 | |
| TJC | RA | 3295 | 0 (0–2) | 1 (0–5) | 4 (0–9) | <0.001† |
| PsA | 956 | 0 (0–2) | 1 (0–4) | 4 (0–9) | <0.001† | |
| ASDAS | PsA | 823 | 2 (1.4–2.7) | 2.6 (2.1–3.55) | 3.45 (2.7–3.95) | <0.001† |
| SpA | 697 | 2 (1.4–2.8) | 2.9 (2.2–3.3) | 3.2 (2.6–3.9) | <0.001† | |
| BASMI-365 | PsA | 299 | 10 (0–20) | 10 (0–30) | 20 (10–30) | 0.004 |
| SpA | 921 | 10 (0–40) | 20 (10–30) | 20 (10–40) | 0.010 | |
| Biochemistry | ||||||
| CRP mg/l | RA | 3231 | 4 (2–9) | 4 (1–9) | 4 (2–10) | 0.067 |
| PsA | 914 | 3 (1–6) | 3 (1–7) | 4 (2–7) | 0.446 | |
| SpA | 775 | 3 (1–7) | 3 (1–7) | 3 (1–8) | 0.736 | |
| RF n(%) | RA | 3091* | 1388 (78) | 575 (78) | 455 (78) | 0.968 |
| antiCCP n(%) | RA | 1908* | 579 (53) | 221 (48) | 173 (48) | 0.122 |
| HLA-B27 n(%) | PsA | 128* | 36 (60) | 21 (58) | 13 (41) | 0.180 |
| SpA | 367* | 167 (82) | 61 (71) | 45 (58) | 0.002 |
All values are the median (Q1-Q3) unless otherwise specified. Group differences were tested using Kruskal-Wallis test or Chi-square test.
a: Refers to the fraction of women in each subgroup of PDQ classification. b: Time since diagnosis. c: Receives a combination of DMARDs. d: Have received more than one biologic agent. e: Currently treated with DMARDs and previously treated with a biologic agent.
† Remain significant after adjusting for multiple testing.
*Number of patients with available information (pos/neg).
PDQ-score: painDETECT Questionnaire score; DMARDs: disease modifying anti-rheumatic drugs; Bio: biological agent; PROs: patient reported outcomes; VAS: visual analogue scale (mm); GH: global health; DAS28-CRP: disease activity score 28 joints; CRP: C- reactive protein; SJC: swollen joint count; TJC: tender joint count. HAQ: health assessment questionnaire; ASDAS: ankylosing spondylitis disease activity score; BASDAI: Bath ankylosing spondylitis disease activity index; BASMI 365: Bath ankylosing spondylitis metrology index attained within the last year; RF: rheumatoid factor; antiCCP: cyclic citrullinated peptide antibody; HLA-B27: human leucocyte antibody, subtype B27.